Journal
Journal of clinical endocrinology & metabolism
Publication Date
2-17-2022
Volume
107
Issue
3
First Page
813
Last Page
824
Document Type
Open Access Publication
DOI
10.1210/clinem/dgab729
Rights and Permissions
Agnès Linglart, Erik A Imel, Michael P Whyte, Anthony A Portale, Wolfgang Högler, Annemieke M Boot, Raja Padidela, William van’t Hoff, Gary S Gottesman, Angel Chen, Alison Skrinar, Mary Scott Roberts, Thomas O Carpenter, Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia, The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 3, March 2022, Pages 813–824, https://doi.org/10.1210/clinem/dgab729. https://academic.oup.com/jcem/article/107/3/813/6391269?login=true. © The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.
Recommended Citation
Linglart, Agnès; Imel, Erik A; Whyte, Michael P; Portale, Anthony A; Högler, Wolfgang; Boot, Annemieke M; Padidela, Raja; Van't Hoff, William; Gottesman, Gary S; Chen, Angel; Skrinar, Alison; Scott Roberts, Mary; and Carpenter, Thomas O, "Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia." Journal of clinical endocrinology & metabolism. 107, 3. 813 - 824. (2022).
https://digitalcommons.wustl.edu/oa_4/3199
Department
ICTS (Institute of Clinical and Translational Sciences)
